Midjourney Announces Ultrasonic CT Full-Body Scanner

Midjourney launched a new business unit called Midjourney Medical and introduced a proposed whole-body ultrasound system branded "Ultrasonic CT." Per Midjourney's Medical page, the system is described as producing a full-body scan in 60 seconds without radiation or strong magnetic fields. The company states a target to deploy 50,000 scanners worldwide over the next 6 years and to perform "a billion full-body scans every month." RadiologyBusiness reports a previously disclosed co-development and licensing agreement with Butterfly Network worth up to $74 million, including a $15 million one-time payment and $10 million annual licensing fees, with up to $9 million in milestone payments referenced in a filing, and says the prototype integrates 40 Butterfly Ultrasound-on-Chip modules per system. The Verge and other outlets report widespread skepticism from medical imaging specialists and radiologists about the evidence presented to date.

Per reporting in RadiologyBusiness and Midjourney's own site, the proposed device is ultrasound-based and described as combining multiple ultrasound-on-chip modules into a single system. Midjourney's promotional text frames the approach as a "totally new form of medical imaging" and compares it to MRI on scan speed and accessibility. RadiologyBusiness quotes Butterfly saying future system versions are "expected to utilize substantially more imaging modules," indicating a planned modular scaling approach. Public materials provided so far do not include peer-reviewed performance metrics, independent validation datasets, or regulatory-clearance documentation in publicly available filings, according to The Verge.

Whole-body and extended-field ultrasound concepts have circulated in research and product efforts for decades, but they face known physics and clinical-utility limits such as acoustic windowing, bone and air interference, variable soft-tissue contrast versus MRI, and operator-dependent image acquisition. Independent validation typically requires phantom studies, blinded reader studies, and clinical trials that compare sensitivity and specificity against established modalities. Companies proposing fast, large-scale screening systems commonly need to publish peer-reviewed results and secure regulatory clearances before clinical deployment.

When consumer-facing AI labs announce hardware moves into regulated healthcare, observers focus on three gates: reproducible technical performance, regulatory approval, and a viable reimbursement or consumer-pay business model. Midjourney's public claims about deployment scale and throughput, as reported on its site and by RadiologyBusiness, are large compared with existing imaging infrastructure. The Verge reports that several medical imaging specialists say Midjourney has not yet provided the kind of evidence clinicians expect. Butterfly Network's involvement and the cited financial terms are notable because they link the project to an established ultrasound-on-chip supplier and to a public company with SEC disclosures. Astral Codex Ten provides a substantive independent technical analysis of the scanner claims.

For practitioners: monitor for peer-reviewed performance papers or preprints; independent phantom and clinical validation data; regulatory filings or clearances with agencies such as the FDA; details on image resolution, penetration depth, and artifact profiles; interoperable output formats and DICOM compatibility; and additional contractual disclosures from Butterfly Network or other partners.